Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News

News :

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

Zealand Pharma Aktieselskabet : increases its share capital as a consequence of exercise of employee warrants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/14/2018 | 09:23am CET

Company announcement – No. 31 / 2018

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Copenhagen, December 14, 2018Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 28,000 divided into 28,000 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre specified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand’s warrant programs, see the company’s Articles of Association, which are available on the website: www.zealandpharma.com.

The exercise price was DKK 75.90 per share and the total proceeds to Zealand from the capital increase amount to DKK 2,125,200.00.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand’s general meetings. Zealand has only one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 30,786,827 divided into 30,786,827 shares with a nominal value of DKK 1 each.

The amendment to Zealand’s Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

Attachment

  • 31-18_1214_ZealandPharma_announcement_capital increase

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
09:23aZEALAND PHARMA AKTIESELSKABET : increases its share capital as a consequence of exercise of employee warrants
AQ
09:22aHAYAT COMMUNICATIONS : Lebanese newspapers' headlines for December 14, 2018
AQ
09:22aMOODY'S CHANGES OUTLOOK FOR SBB : s B1 rating to positive from stable
AQ
09:20aAIRBUS : names Mhun as next programmes chief
RE
09:20aASPEN PHARMACARE : Pre-Close Statement Clarification
PU
09:20aSUMITOMO MITSUI FINANCIAL : Japan bank SMFG names finance chief Ota as CEO
RE
09:20aGEK TERNA REAL ESTATE CONSTRUCTION : Purchase of GEK TERNA's Shares
PU
09:20aOPTIBIOTIX HEALTH : Issue of Convertible Loan Notes by ProBiotix and Related Party Transaction
PU
09:20aALTONA ENERGY : Pyrolysis Update
PU
09:19aU.S. recession risks jump, Fed rate hike expectations slump - Reuters poll
RE
Latest news
Advertisement